Pulmonx Q2 revenue up 15% to $23.9M but cuts FY2025 guidance to $90-92M

Pulmonx Corp

2025-Q2 EPS reported -$0.74 revenue$46,397,000

Revenue $23.9M (+15% YoY); U.S. $14.7M (+6%), International $9.1M (+32% constant currency +27%).
Net loss $15.2M ($0.38/sh) vs $15.3M ($0.39/sh) prior year; Adjusted EBITDA loss $8.4M vs $7.6M.
Full-year 2025 revenue guidance cut to $90-92M from $96-98M; OpEx lowered to $128-130M from $133-135M.
Gross margin 72% vs 74% prior year; cash, cash equivalents & marketable securities $84.2M.
Added 12 new Zephyr Valve U.S. treatment centers, trained 26 physicians; over 20k first-time patient engagements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.